2C-G
title: "2C-G" type: doc version: 1 created: 2026-02-28 author: "Wikipedia contributors" status: active scope: public tags: ["2c-(psychedelics)", "designer-drugs", "methyl-compounds", "pihkal", "psychedelic-phenethylamines"] topic_path: "general/2c-psychedelics" source: "https://en.wikipedia.org/wiki/2C-G" license: "CC BY-SA 4.0" wikipedia_page_id: 0 wikipedia_revision_id: 0
::data[format=table title="Infobox drug"]
| Field | Value |
|---|---|
| Verifiedfields | changed |
| Watchedfields | changed |
| verifiedrevid | 477216206 |
| image | 2C-G.svg |
| image_class | skin-invert-image |
| width | 200px |
| image2 | 2C-G-3d-sticks.png |
| image_class2 | bg-transparent |
| width2 | 175px |
| routes_of_administration | Oral |
| class | Serotonergic psychedelic; Hallucinogen |
| ATC_prefix | None |
| legal_status | In general Unscheduled |
| duration_of_action | 18–30 hours |
| CAS_number_Ref | |
| CAS_number | 207740-18-9 |
| PubChem | 22238091 |
| ChemSpiderID_Ref | |
| ChemSpiderID | 21106224 |
| UNII_Ref | |
| UNII | DTG7FMO01J |
| ChEMBL_Ref | |
| ChEMBL | 127202 |
| synonyms | 2C-G-0; 2,5-Dimethoxy-3,4-dimethylphenethylamine; 3,4-Dimethyl-2,5-dimethoxyphenethylamine; 3-Methyl-2C-D |
| IUPAC_name | 2-(2,5-dimethoxy-3,4-dimethylphenyl)ethan-1-amine |
| C | 12 |
| SMILES | COc1c(C)c(C)c(cc1CCN)OC |
| StdInChI_Ref | |
| StdInChI | 1S/C12H19NO2/c1-8-9(2)12(15-4)10(5-6-13)7-11(8)14-3/h7H,5-6,13H2,1-4H3 |
| StdInChIKey_Ref | |
| StdInChIKey | NFOHGLKGLZIHJQ-UHFFFAOYSA-N |
| :: |
| Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 477216206 | drug_name = | image = 2C-G.svg | image_class = skin-invert-image | width = 200px | caption = | image2 = 2C-G-3d-sticks.png | image_class2 = bg-transparent | width2 = 175px | caption2 =
| pronounce = | tradename = | Drugs.com = | MedlinePlus = | licence_CA = | licence_EU = | DailyMedID = | licence_US = | pregnancy_AU = | pregnancy_category = | dependency_liability = | addiction_liability = | routes_of_administration = Oral | class = Serotonergic psychedelic; Hallucinogen | ATC_prefix = None | ATC_suffix =
| legal_status = In general Unscheduled
| bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = 18–30 hours | excretion =
| CAS_number_Ref = | CAS_number = 207740-18-9 | CAS_supplemental = | PubChem = 22238091 | PubChemSubstance = | IUPHAR_ligand = | DrugBank = | ChemSpiderID_Ref = | ChemSpiderID = 21106224 | UNII_Ref = | UNII = DTG7FMO01J | KEGG = | ChEBI = | ChEMBL_Ref = | ChEMBL = 127202 | NIAID_ChemDB = | PDB_ligand = | synonyms = 2C-G-0; 2,5-Dimethoxy-3,4-dimethylphenethylamine; 3,4-Dimethyl-2,5-dimethoxyphenethylamine; 3-Methyl-2C-D
| IUPAC_name = 2-(2,5-dimethoxy-3,4-dimethylphenyl)ethan-1-amine | C=12 | H=19 | N=1 | O=2 | SMILES = COc1c(C)c(C)c(cc1CCN)OC | StdInChI_Ref = | StdInChI = 1S/C12H19NO2/c1-8-9(2)12(15-4)10(5-6-13)7-11(8)14-3/h7H,5-6,13H2,1-4H3 | StdInChIKey_Ref = | StdInChIKey = NFOHGLKGLZIHJQ-UHFFFAOYSA-N
2C-G, or 2C-G-0, also known as 3,4-dimethyl-2,5-dimethoxyphenethylamine or as 3-methyl-2C-D, is a psychedelic phenethylamine of the 2C family. First synthesized by Alexander Shulgin, it has structural and pharmacodynamic properties similar to 2C-D and Ganesha (G). The drug has a number of known homologues, which are known as the 2C-G series of compounds.
Use and effects
In Alexander Shulgin's book PiHKAL (Phenethylamines I Have Known and Loved), the dose range is listed as 20 to 35mg orally. Effects are similar to the related Ganesha, and are extremely long lasting; the duration is 18 to 30hours. Visual effects are muted or absent, and it is described as an "insight-enhancer". Unlike other members of the 2C series, 2C-G is nearly as potent as its amphetamine form.
Interactions
Chemistry
Synthesis
The chemical synthesis of 2C-G has been described.
Homologues
Several homologues of 2C-G (2C-G-0) were also synthesized and/or tested by Alexander Shulgin. These include 2C-G-3, 2C-G-5, and 2C-G-N. Some, such as 2C-G-1, 2C-G-2, 2C-G-4, and 2C-G-6, are possible to synthesize in principle but impossible or extraordinarily difficult to do so in practice.
::data[format=table]
| Compound | Details | Structure |
|---|---|---|
| 2C-G-1 | CAS #: 2888537-47-9 | |
| [[File:2C-G-1.png | 125px | class=skin-invert-image]] |
| 2C-G-2 | CAS #: 2888537-48-0 | |
| [[File:2C-G-2.png | 125px | class=skin-invert-image]] |
| 2C-G-3 | CAS #: 207740-19-0 | |
| [[File:2C-G-3-Chemdraw.png | 125px | class=skin-invert-image]] |
| 2C-G-4 | CAS #: 952006-59-6 | |
| [[File:2C-G-4.svg | 125px | class=skin-invert-image]] |
| 2C-G-5 | CAS #: 207740-20-3 | |
| [[File:2C-G-5.svg | 125px | class=skin-invert-image]] |
| 2C-G-6 | CAS #: 2888537-49-1 | |
| [[File:2C-G-6.png | 125px | class=skin-invert-image]] |
| 2C-G-N | CAS #: 207740-21-4 | |
| [[File:2C-G-N-Chemdraw.png | 125px | class=skin-invert-image]] |
| :: |
History
2C-G was first described in the literature by Alexander Shulgin in his 1991 book PiHKAL (Phenethylamines I Have Known and Loved).
Society and culture
Legal status
Canada
As of October 31, 2016; 2C-G is a controlled substance (Schedule III) in Canada.
United Kingdom
2C-G and all other compounds featuring in PiHKAL are Class A drugs in the United Kingdom.
United States
In the United States 2C-G is considered a Schedule I controlled substance as a positional isomer of 2C-E and DOM.
References
References
- (1991). "PiHKAL: A Chemical Love Story". Transform Press.
- (4 May 2016). "Regulations Amending the Food and Drug Regulations (Part J — 2C-phenethylamines)".
- (February 2023). "Lists of: Scheduling Actions - Controlled Substances - Regulated Chemicals". Drug Enforcement Administration.
- [[Drug Enforcement Administration]]. (3 December 2007). "Definition of “Positional Isomer” as It Pertains to the Control of Schedule I Controlled Substances".
::callout[type=info title="Wikipedia Source"] This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page. ::